Understanding the interactions of boron compounds with A431 epidermoid carcinoma cells overexpressing EGFR (Figure 5A) provides an opportunity to improve the performance of B-ASO delivery without transfection reagents in the treatment of cancer using BNCT. The gene discussed is EGFR; the disease is cancer.